Cargando…

Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation

The farnesoid X receptor (FXR) is involved in glucose and lipid metabolism regulation, which makes it an attractive target for the metabolic syndrome, dyslipidemia, atherosclerosis, and type 2 diabetes. In order to find novel FXR agonists, a structure-based pharmacophore model collection was develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuster, Daniela, Markt, Patrick, Grienke, Ulrike, Mihaly-Bison, Judit, Binder, Markus, Noha, Stefan M., Rollinger, Judith M., Stuppner, Hermann, Bochkov, Valery N., Wolber, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254253/ https://www.ncbi.nlm.nih.gov/pubmed/22018919 http://dx.doi.org/10.1016/j.bmc.2011.09.056

Ejemplares similares

Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum
por: Grienke, Ulrike, et al.
Publicado: (2011)

Pharmacophore-based discovery of a novel cytosolic phospholipase A(2)α inhibitor
por: Noha, Stefan M., et al.
Publicado: (2012)

Pharmacophore Modeling and Virtual Screening for Novel Acidic Inhibitors of Microsomal Prostaglandin E(2) Synthase-1 (mPGES-1)
por: Waltenberger, Birgit, et al.
Publicado: (2011)

Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part II: Identification of enzyme inhibitors from Prasaplai, a Thai traditional medicine
por: Waltenberger, Birgit, et al.
Publicado: (2011)

Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques
por: Noha, Stefan M., et al.
Publicado: (2011)

Identification of Novel Liver X Receptor Activators by Structure-Based Modeling
por: von Grafenstein, Susanne, et al.
Publicado: (2012)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Virtual screening for the discovery of bioactive natural products
por: Rollinger, Judith M., et al.
Publicado: (2008)

Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening
por: Temml, Veronika, et al.
Publicado: (2017)

Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening
por: Temml, Veronika, et al.
Publicado: (2014)

Biochemometry-Based Discovery of Phenylpropanoids from Azadirachta indica Fruits as Inhibitors of In Vitro Osteoclast Formation
por: Tahir, Ammar, et al.
Publicado: (2022)

Efficient 3D pharmacophore alignment as a tool for structure-based modeling and scoring
por: Wolber, Gerhard
Publicado: (2008)

Combining pharmacophore- and MD-based modelling for phase II metabolism prediction
por: Rakers, Christin, et al.
Publicado: (2014)

Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo
por: Fakhrudin, N, et al.
Publicado: (2014)

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Miyata, Sachiho, et al.
Publicado: (2021)

Editorial: Rising stars in ethnopharmacology: 2021
por: Grienke, Ulrike, et al.
Publicado: (2023)

(1)H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues
por: Grienke, Ulrike, et al.
Publicado: (2019)

3D pharmacophore alignments: does improved geometric accuracy affect virtual screening performance?
por: Wolber, Gerhard, et al.
Publicado: (2010)

Discovery and resupply of pharmacologically active plant-derived natural products: A review
por: Atanasov, Atanas G., et al.
Publicado: (2015)

In Silico Workflow for the Discovery of Natural Products Activating the G Protein-Coupled Bile Acid Receptor 1
por: Kirchweger, Benjamin, et al.
Publicado: (2018)

Preparative supercritical fluid chromatography for lipid class fractionation—a novel strategy in high-resolution mass spectrometry based lipidomics
por: Schoeny, Harald, et al.
Publicado: (2020)

Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae
por: Grienke, Ulrike, et al.
Publicado: (2016)

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
por: Sepe, Valentina, et al.
Publicado: (2016)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Tautomerism in structure-based 3D pharmacophore modeling
por: Seidel, Thomas, et al.
Publicado: (2008)

Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

Drugs from nature targeting inflammation (DNTI): a successful Austrian interdisciplinary network project
por: Waltenberger, Birgit, et al.
Publicado: (2016)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Natural Product 2-Oxokolavenol Is a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

Pharmacophore‐guided Virtual Screening to Identify New β(3)‐adrenergic Receptor Agonists
por: Ujiantari, Navista Sri Octa, et al.
Publicado: (2022)

A ligand-based 3D pharmacophore model for the μ opioid receptor: application to the morphinan class of opioids
por: Asim, Muhammad Faheem, et al.
Publicado: (2010)

Discovery of anti-SARS-CoV-2 secondary metabolites from the heartwood of Pterocarpus santalinus using multi-informative molecular networking
por: Wasilewicz, Andreas, et al.
Publicado: (2023)

Using structure- and Ligand-based pharmacophores as filters to discriminate Human Aryl Sulfotransferase 1A1 (SUL1A1) binders into substrates and inhibitors
por: Soliman, Salwa M, et al.
Publicado: (2014)

Biochemometry identifies ostruthin as pluripotent antimicrobial and anthelmintic agent from masterwort
por: Zwirchmayr, Julia, et al.
Publicado: (2023)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

Natural products modulating the hERG channel: heartaches and hope
por: Kratz, Jadel M., et al.
Publicado: (2017)

(1)H NMR-Based Biochemometric Analysis of Morus alba Extracts toward a Multipotent Herbal Anti-Infective
por: Langeder, Julia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0aacb93p7cdlao9ve5eud93v6j